MRI scans of a healthy brain (left) and a brain with amyloid plaques, a sign of Alzheimer’s disease (right)
Mark and Mary Stevens Neuroimaging and Informatics Institute/Scientific Photo Library
Some are hailing 2023 as the beginning of a turning point in efforts to combat Alzheimer’s disease. Two countries, the United States and Japan, have approved a drug called lecanemab, the first treatment that not only relieves symptoms but actually slows their progression. A number of other countries, including the UK and Australia, are now considering following suit, but the drug is not without criticism.
Lecanemab received approval in…
Source: www.newscientist.com
